Purcell Y, et al. - In this investigation involving 115 patients (mean 65.1 ± 10.5 years [range 26–87]), researchers evaluated the influence of pretreatment tumor growth rate (TGR) on modified response evaluation criteria in solid tumors (mRECIST) objective response (OR) following a first session of selective transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). They included individuals with 169 tumors (mean 34.2 ± 29.3 mm [10–160]), undergoing the first session of selective TACE for the treatment of HCC between 2011 and 2016. Overall 88/189 and 46/189 tumors exhibited complete response and partial response. On the other hand, 32/189 displayed stable disease (SD), and 3/189 were progressive disease on computed tomography at 1-month post-TACE. Data reported that the mean pretreatment TGR was 12.0 ± 15.4 (−3.2–90.4) %/month. Overall, the authors concluded that pretreatment TGR is highly variable in tumor response prediction in HCC before TACE with a U-shaped distribution. This provides insight into tumor biology that can be used to better stratify patients during pretreatment research.